Bristol Myers Squibb ( BMY Quick Quote BMY - Free Report) announced positive top-line results from the TRANSFORM study on Breyanzi (lisocabtagene maraleucel), a CD19-directed CAR T cell therapy.
Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy. It was approved in February 2021 for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
The TRANSFORM study has been designed to evaluate Breyanzi’s potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard-of-care regimen of high-dose chemotherapy and autologous stem-cell transplant.
The results of a pre-specified interim analysis conducted by an independent review committee showed that the study met its primary endpoint. Data showed a clinically meaningful and highly statistically significant improvement in event-free survival, as well as key secondary endpoints of complete response rate and progression-free survival compared to standard of care. The safety results were consistent with the known safety profile of Breyanzi for the treatment of LBCL in the third-line setting.
Bristol Myers will complete an evaluation of the TRANSFORM data and looks forward to sharing the results at an upcoming medical conference, as well as with health authorities.
Bristol-Myers’ shares have gained 7.9% year to date against the
industry's decline of 1.9%.
Image Source: Zacks Investment Research
The company’s performance in the first quarter of 2021 was dismal as immuno-oncology drug Opdivo’s sales declined as competition is stiff from the likes of
Merck’s ( MRK Quick Quote MRK - Free Report) Keytruda. Moreover, Revlimid sales weren’t impressive either.
Nevertheless, the recent approval of new drugs adds a new stream of revenues, which should propel growth in the coming quarters.
In March, the company and partner bluebird bio, Inc. (
BLUE Quick Quote BLUE - Free Report) obtained the FDA approval for Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory MM.
Last month, the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector includes
Repligen Corporation ( RGEN Quick Quote RGEN - Free Report) , which carries a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Repligen’s earnings estimates for 2021 have increased to $2.21 from $1.91 in the past 90 days.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>